Wechselwirkungen · Amgevita
AMGEVITA 20 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled syringe AMGEVITA 80 mg solution for injection in pre-filled syringe AMGEVITA 40 mg solution for injection in pre-filled pen AMGEVITA 80 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 69
HOS-224924 · Präparat HOS-217372
Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking adalimumab as monotherapy and those taking concomitant methotrexate. Antibody formation was lower when adalimumab was given together with methotrexate in comparison with use as monotherapy. Administration of adalimumab without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T02:00:00Z · SHA-256 e60d722f3b6745489b45f5c78ae97b6371cdaa2129d753a34a831ca4ba40a8b5 · Passage f4135ee2215f6ca7a3bfe306ef48464322e6039f1d5e0ed83f1f6e9906284b09 · Zeichen 0–497 im Abschnitt